Arcutis Biotherapeutics, Inc.

Good day, and thank you for standing by. Welcome to the Arcudous Biotherapeutics 2025 Third Quarter Financial Results and Investor Day presentation. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To submit questions, please use the question submission field located at the bottom of your webcast interface. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Brian Shawcoff, Head of Investor Relations. Please go ahead.

Thank you. Good morning, everyone. And thank you for joining us today to review our third quarter 2025 financial results and business update. And for our extended investor day presentation. Slides for today's call are available in the investor section of the Arcutus website. Joining me on the call today are Frank Watanabe, President and CEO of Arcutis, Todd Edwards, Chief Commercial Officer, Patrick Burnett, Chief Medical Officer, and Mata Varavan, Chief Financial Officer. We will also be joined later in the call by Douglas DeRiggiero, a Certified Physician Assistant and Doctor of Medical Science who has specialized in dermatology for the past 25 years and is the founding president of the Georgia Dermatology Physician Assistance Society. I would like to remind everyone that we will be making forward looking statements during this call. These statements are subject to certain risks and uncertainties and our actual results may differ. We encourage you to review all the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand it over to Frank for a brief introduction of today's call.

Thanks, Brian, and thanks to all of you for joining us today and freeing up some additional time in your calendars for what we believe will be a compelling review of the strong foundation of our business today and a more in-depth look at our strategy to sustain our growth in the future. We'll start today's call by reviewing our commercial and financial results for the third quarter. As you'll hear from Todd and Latha in a moment, we achieved yet another strong quarter with robust net product revenue growth and continued steady growth of prescriptions across all approved formulations and indications for Zareef. We'll then move on to the Investor Day presentation where we'll do a deep dive into why we are excited by and confident in the future of Arcutis and our unique potential to address key unmet needs for patients impacted by immune mediated dermatological diseases. Today's discussion on our corporate strategy is timely and pertinent as we approach cash flow positivity, enabling us to self-fund investments in our business that will sustain the continued growth for Arcutis. Our excitement is grounded first in the outstanding growth opportunities for Zareve, a revolutionary topical agent that is already reshaping the treatment of chronic inflammatory skin diseases, an impact we foresee only amplifying in the years ahead. As you'll hear today, we have multiple opportunities to grow and further expand our Zareef business, and we have the capabilities and resources to exploit those opportunities. We'll also go into more detail today about our exciting pipeline building efforts, starting with ARQ234, a novel biologic with best-in-class potential to address a large unmet need in atopic dermatitis. Complementing the Zareef franchise, ARQ234 and future pipeline opportunities will enable us to extend our mission to champion meaningful innovation for patients impacted by immune-mediated skin conditions and strengthen Arcutis' position as one of the industry's most consequential medical dermatology powerhouses. I'd also like to take a moment to thank the Arcutis team for their efforts and commitment to bringing better outcomes to patients living with serious skin diseases. Their unwavering dedication underlays our achievements to date and will be the foundation for the ambitious plans we discussed today. So thank you all again for taking the time to join us today. And now I'll turn the call over to Todd for our Q3 commercial update.